Sign in Subscribe
Cancer

SpotitEarly's Cancer Detection Technology Achieves 94 Percent Accuracy Rate, Attracts Top Investors and Academic Medical Centers

Strategic Insights

— 1 min read

SpotitEarly, a biotech startup, has launched in the U.S. market with a novel cancer detection technology that harnesses the power of artificial intelligence and canines to analyze volatile organic compounds in breath samples. The company has raised $20.3 million in funding and has attracted top investors, researchers, and academic medical centers. The at-home test has been found to have a 94 percent accuracy rate in a two-year clinical trial involving 1,400 individuals, published in Nature's Scientific Reports.

Key Takeaways:

  • SpotitEarly's cancer detection technology has achieved a 94 percent accuracy rate in a two-year clinical trial involving 1,400 individuals.
  • The company has raised $20.3 million in funding and has attracted top investors, including Hanaco VC, Menomedin VC, Jeff Swartz, and Avishai Abrahami.
  • SpotitEarly has been awarded several grants, most notably from the BIRD Foundation, and has formed partnerships with academic medical centers, including the University of Pennsylvania.
  • The company's bio-hybrid approach to cancer screening offers a simple at-home breath test for the four most common types of cancer.
  • SpotitEarly's proprietary method uses an innovative diagnostic process that taps into the powerful scent detection of trained canines, analyzed by its LUCID AI technology.
  • The company aims to revolutionize cancer screening by providing a non-invasive, affordable, and accessible solution for early detection and prevention of cancer.
  • SpotitEarly has appointed U.S.-based advisors to its scientific board, including Dr. David Sidransky, Dr. Jonathan Fleming, and Dr. Len Lichtenfeld.
  • The company is expanding its research partnerships and has opened its Series A funding round under Regulation D (Reg D), offering accredited investors the opportunity to support further growth.

Statistics:

  • 94% accuracy rate achieved in a two-year clinical trial involving 1,400 individuals.
  • $20.3 million in funding raised by SpotitEarly.
  • The company aims to improve access to cancer screening and enhance early detection rates.
  • Cancer care costs in the U.S. are expected to reach $245 billion by 2030.
  • The at-home test will be made commercially available in the U.S. in 2026.

Sources:

  • https://www.businesswire.com/news/home/20250515336844/en/
  • [Reference to the clinical trial published in Nature's Scientific Reports]

Read more